466 related articles for article (PubMed ID: 8752158)
21. GSTM1 and NAT2 polymorphisms and colon, lung and bladder cancer risk: a case-control study.
Zupa A; Sgambato A; Bianchino G; Improta G; Grieco V; LA Torre G; Campisi B; Traficante A; Aieta M; Cittadini A
Anticancer Res; 2009 May; 29(5):1709-14. PubMed ID: 19443391
[TBL] [Abstract][Full Text] [Related]
22. Impact of inherited polymorphisms in glutathione S-transferase M1, microsomal epoxide hydrolase, cytochrome P450 enzymes on DNA, and blood protein adducts of benzo(a)pyrene-diolepoxide.
Pastorelli R; Guanci M; Cerri A; Negri E; La Vecchia C; Fumagalli F; Mezzetti M; Cappelli R; Panigalli T; Fanelli R; Airoldi L
Cancer Epidemiol Biomarkers Prev; 1998 Aug; 7(8):703-9. PubMed ID: 9718223
[TBL] [Abstract][Full Text] [Related]
23. Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study.
Brockmöller J; Kerb R; Drakoulis N; Staffeldt B; Roots I
Cancer Res; 1994 Aug; 54(15):4103-11. PubMed ID: 8033143
[TBL] [Abstract][Full Text] [Related]
24. Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women.
McGrath M; Michaud D; De Vivo I
BMC Cancer; 2006 Oct; 6():239. PubMed ID: 17026750
[TBL] [Abstract][Full Text] [Related]
25. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population.
Hung RJ; Boffetta P; Brennan P; Malaveille C; Hautefeuille A; Donato F; Gelatti U; Spaliviero M; Placidi D; Carta A; Scotto di Carlo A; Porru S
Int J Cancer; 2004 Jul; 110(4):598-604. PubMed ID: 15122594
[TBL] [Abstract][Full Text] [Related]
26. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10.
Cascorbi I; Roots I; Brockmöller J
Cancer Res; 2001 Jul; 61(13):5051-6. PubMed ID: 11431340
[TBL] [Abstract][Full Text] [Related]
27. A systematic approach to analysing gene-gene interactions: polymorphisms at the microsomal epoxide hydrolase EPHX and glutathione S-transferase GSTM1, GSTT1, and GSTP1 loci and breast cancer risk.
Spurdle AB; Chang JH; Byrnes GB; Chen X; Dite GS; McCredie MR; Giles GG; Southey MC; Chenevix-Trench G; Hopper JL
Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):769-74. PubMed ID: 17416769
[TBL] [Abstract][Full Text] [Related]
28. Genetic polymorphisms of cytochrome P450 CYP1A1 (*2A) and microsomal epoxide hydrolase gene, interactions with tobacco-users, and susceptibility to bladder cancer: a study from North India.
Srivastava DS; Mandhani A; Mittal RD
Arch Toxicol; 2008 Sep; 82(9):633-9. PubMed ID: 18200441
[TBL] [Abstract][Full Text] [Related]
29. Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer.
Hsieh FI; Pu YS; Chern HD; Hsu LI; Chiou HY; Chen CJ
Br J Cancer; 1999 Oct; 81(3):537-41. PubMed ID: 10507782
[TBL] [Abstract][Full Text] [Related]
30. Do smoking and polymorphisms in xenobiotic metabolizing enzymes affect the histological stage and grade of bladder tumors?
Ouerhani S; Rouissi K; Marrakchi R; Riadh Ben Slama M; Sfaxi M; Ayed M; Chebil M; Elgaaied A
Bull Cancer; 2009 May; 96(5):E23-9. PubMed ID: 19467981
[TBL] [Abstract][Full Text] [Related]
31. Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer.
Suzuki S; Muroishi Y; Nakanishi I; Oda Y
J Gastroenterol; 2004; 39(3):220-30. PubMed ID: 15064998
[TBL] [Abstract][Full Text] [Related]
32. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China.
Song DK; Xing DL; Zhang LR; Li ZX; Liu J; Qiao BP
Cancer Detect Prev; 2009; 32(5-6):416-23. PubMed ID: 19303722
[TBL] [Abstract][Full Text] [Related]
33. Association between allelic polymorphisms of metabolizing enzymes (CYP 1A1, CYP 1A2, CYP 2E1, mEH) and occurrence of colorectal cancer in Hungary.
Kiss I; Orsós Z; Gombos K; Bogner B; Csejtei A; Tibold A; Varga Z; Pázsit E; Magda I; Zölyomi A; Ember I
Anticancer Res; 2007; 27(4C):2931-7. PubMed ID: 17695473
[TBL] [Abstract][Full Text] [Related]
34. Cumulative genetic defects in carcinogen metabolism may increase breast cancer risk (The Netherlands).
van der Hel OL; Bueno-de-Mesquita HB; van Gils CH; Roest M; Slothouber B; Grobbee DE; Peeters PH
Cancer Causes Control; 2005 Aug; 16(6):675-81. PubMed ID: 16049806
[TBL] [Abstract][Full Text] [Related]
35. Impact of genetic polymorphisms in cytochrome P450 2E1 and glutathione S-transferases M1, T1, and P1 on susceptibility to esophageal cancer among high-risk individuals in China.
Tan W; Song N; Wang GQ; Liu Q; Tang HJ; Kadlubar FF; Lin DX
Cancer Epidemiol Biomarkers Prev; 2000 Jun; 9(6):551-6. PubMed ID: 10868687
[TBL] [Abstract][Full Text] [Related]
36. Glutathione S-transferase M1, T1 and P1 genetic polymorphisms, cigarette smoking and gastric cancer risk.
Tamer L; Ateş NA; Ateş C; Ercan B; Elipek T; Yildirim H; Camdeviren H; Atik U; Aydin S
Cell Biochem Funct; 2005; 23(4):267-72. PubMed ID: 15473001
[TBL] [Abstract][Full Text] [Related]
37. Dietary intake of vegetables and fruits and the modification effects of GSTM1 and NAT2 genotypes on bladder cancer risk.
Lin J; Kamat A; Gu J; Chen M; Dinney CP; Forman MR; Wu X
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2090-7. PubMed ID: 19549811
[TBL] [Abstract][Full Text] [Related]
38. Dietary isothiocyanates, GSTM1, GSTT1, NAT2 polymorphisms and bladder cancer risk.
Zhao H; Lin J; Grossman HB; Hernandez LM; Dinney CP; Wu X
Int J Cancer; 2007 May; 120(10):2208-13. PubMed ID: 17290402
[TBL] [Abstract][Full Text] [Related]
39. Genetic polymorphisms of CYP2D6, GSTM1, and GSTT1 genes and bladder cancer risk in North India.
Sobti RC; Al-Badran AI; Sharma S; Sharma SK; Krishan A; Mohan H
Cancer Genet Cytogenet; 2005 Jan; 156(1):68-73. PubMed ID: 15588859
[TBL] [Abstract][Full Text] [Related]
40. XPD codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk.
Stern MC; Johnson LR; Bell DA; Taylor JA
Cancer Epidemiol Biomarkers Prev; 2002 Oct; 11(10 Pt 1):1004-11. PubMed ID: 12376500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
